Literature DB >> 20467784

Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y.

Ayhan Bilir1, Mine Erguven, Nuray Yazihan, Esin Aktas, Gulperi Oktem, Akin Sabanci.   

Abstract

The aim of this work is to investigate whether clomipramine (CIM) and lithium chloride (LiCl) potentiate the cytotoxicity of vinorelbine (VNR) on SH-SY5Y human neuroblastoma cells in vitro and whether midkine (MK) can be a resistance factor for these treatments. Four groups of experiments were performed for 96 h using both monolayer and spheroid cultures of SH-SY5Y cells: (1) control group, (2) singly applied VNR, CIM, and LiCl, (3) VNR with CIM, and (4) VNR with LiCl. Their effects on monolayer and spheroid cultures were determined by evaluating cell proliferation, bromodeoxyuridine labeling index (BrdU-LI), apoptosis, cyclic adenosine monophosphate (cAMP) and midkine levels, colony-forming efficiency, spheroid size, and ultrastructure. In comparison with the control group, single and combination drug treatments significantly reduced the proliferation index (PI) for 96 h. The most potent reduction of PI was observed with VNR in combination with CIM and LiCl for all time intervals. VNR with CIM and LiCl seemed to be ineffective in reducing BrdU-LI of both monolayer cell and spheroid cultures, spheroid size, and cAMP level. VNR with LiCl increased apoptosis at 24 h, however VNR with CIM increased apoptosis at 96 h. VNR was the most potent drug in inhibiting colony-forming efficiency. The combination of VNR with CIM was the most potent in reducing midkine levels among all groups. Interestingly, the combination of VNR with LiCl led to both nuclear membrane breakdown and disappearance of the cellular membranes inside the spheroids. Both CIM and LiCl seemed to potentiate VNR-induced cytotoxicity, and MK was not a resistance factor for VNR, LiCl, and CIM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467784     DOI: 10.1007/s11060-010-0209-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  56 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Cyclin A2 regulates nuclear-envelope breakdown and the nuclear accumulation of cyclin B1.

Authors:  Delquin Gong; Joseph R Pomerening; Jason W Myers; Christer Gustavsson; Joshua T Jones; Angela T Hahn; Tobias Meyer; James E Ferrell
Journal:  Curr Biol       Date:  2007-01-09       Impact factor: 10.834

Review 3.  RNA interference as an anticancer therapy: a patent perspective.

Authors:  Derek M Dykxhoorn
Journal:  Expert Opin Ther Pat       Date:  2009-04       Impact factor: 6.674

4.  Long-term exposure to low lithium concentrations stimulates proliferation, modifies stress protein expression pattern and enhances resistance to oxidative stress in SH-SY5Y cells.

Authors:  M S Allagui; R Nciri; M F Rouhaud; J C Murat; A El Feki; F Croute; C Vincent
Journal:  Neurochem Res       Date:  2008-08-08       Impact factor: 3.996

5.  Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.

Authors:  Yoshifumi Takei; Kenji Kadomatsu; Tatsunori Goto; Takashi Muramatsu
Journal:  Cancer       Date:  2006-08-15       Impact factor: 6.860

6.  Chlorimipramine: a novel anticancer agent with a mitochondrial target.

Authors:  E Daley; D Wilkie; A Loesch; I P Hargreaves; D A Kendall; G J Pilkington; T E Bates
Journal:  Biochem Biophys Res Commun       Date:  2005-03-11       Impact factor: 3.575

7.  Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma.

Authors:  Ayhan Bilir; Mine Erguven; Gulperi Oktem; Aysegul Ozdemir; Atilla Uslu; Esin Aktas; Benjamin Bonavida
Journal:  Int J Oncol       Date:  2008-04       Impact factor: 5.650

8.  Midkine secretion protects Hep3B cells from cadmium induced cellular damage.

Authors:  Nuray Yazihan; Haluk Ataoglu; Ethem Akcil; Burcu Yener; Bulent Salman; Cengiz Aydin
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

9.  Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3.

Authors:  Michal O Nowicki; Nina Dmitrieva; Andrew M Stein; Jennifer L Cutter; Jakub Godlewski; Yoshinaga Saeki; Masayuki Nita; Michael E Berens; Leonard M Sander; Herbert B Newton; E Antonio Chiocca; Sean Lawler
Journal:  Neuro Oncol       Date:  2008-08-20       Impact factor: 12.300

10.  Effect of alpha 2-adrenoceptor blockade on lithium action in the rat brain.

Authors:  M Laura Cuffi; Lourdes Carbonell; Frederic Mármol; José Giménez; Javier Forn
Journal:  Brain Res       Date:  2003-12-19       Impact factor: 3.252

View more
  15 in total

1.  Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Seval Korkmaz; Esin Aktas; Cem Ovalioglu; Tolga Dundar; Hakan Seyithanoglu
Journal:  Oncol Lett       Date:  2011-10-04       Impact factor: 2.967

2.  Slow down to stay alive: HER4 protects against cellular stress and confers chemoresistance in neuroblastoma.

Authors:  Yingqi Hua; Kirill Gorshkov; Yanwen Yang; Wenyi Wang; Nianxiang Zhang; Dennis P M Hughes
Journal:  Cancer       Date:  2012-03-13       Impact factor: 6.860

3.  A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.

Authors:  Madhuri Kalathur; Alberto Toso; Jingjing Chen; Ajinkya Revandkar; Claudia Danzer-Baltzer; Ilaria Guccini; Abdullah Alajati; Manuela Sarti; Sandra Pinton; Lara Brambilla; Diletta Di Mitri; Giuseppina Carbone; R Garcia-Escudero; Alessandro Padova; Letizia Magnoni; Alessia Tarditi; Laura Maccari; Federico Malusa; Ravi Kiran Reddy Kalathur; Lorenzo A Pinna; Giorgio Cozza; Maria Ruzzene; Nicolas Delaleu; Carlo V Catapano; Ian J Frew; Andrea Alimonti
Journal:  Nat Commun       Date:  2015-06-18       Impact factor: 14.919

Review 4.  Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment.

Authors:  Antonio Asensi-Cantó; María Dolores López-Abellán; Verónica Castillo-Guardiola; Ana María Hurtado; Mónica Martínez-Penella; Ginés Luengo-Gil; Pablo Conesa-Zamora
Journal:  Cancers (Basel)       Date:  2022-07-01       Impact factor: 6.575

5.  Establishment and characterization of xenograft models of human neuroblastoma bone metastasis.

Authors:  Hongyu Zhao; Weisong Cai; Shuai Li; Zuke Da; Hanxue Sun; Liang Ma; Yaoxin Lin; Debao Zhi
Journal:  Childs Nerv Syst       Date:  2012-09-16       Impact factor: 1.475

6.  Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines.

Authors:  Hongyu Zhao; Weisong Cai; Shuai Li; Zuke Da; Hanxue Sun; Liang Ma; Yaoxin Lin; Debao Zhi
Journal:  Childs Nerv Syst       Date:  2013-04-05       Impact factor: 1.475

7.  Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine.

Authors:  Mine Erguven; Ayhan Bilir; Nuray Yazihan; Ezgi Ermis; Akin Sabanci; Esin Aktas; Yavuz Aras; Vehbi Alpman
Journal:  Cancer Cell Int       Date:  2011-06-08       Impact factor: 5.722

8.  Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro.

Authors:  Ayhan Bilir; Mine Erguven; Ezgi Ermis; Mine Sencan; Nuray Yazihan
Journal:  J Gynecol Oncol       Date:  2011-12-05       Impact factor: 4.401

9.  Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options.

Authors:  J M Loupe; P J Miller; D R Ruffin; M W Stark; A D Hollenbach
Journal:  Oncogenesis       Date:  2015-03-30       Impact factor: 7.485

10.  XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway.

Authors:  Xiao-Hong Tian; Wei-Jian Hou; Yan Fang; Jun Fan; Hao Tong; Shu-Ling Bai; Qu Chen; He Xu; Yan Li
Journal:  J Exp Clin Cancer Res       Date:  2013-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.